Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: a Single Centre, Randomised, Placebo-controlled Trial
Latest Information Update: 26 Dec 2024
At a glance
- Drugs Sirolimus (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions
- Acronyms CALM
- 20 Dec 2024 Planned number of patients changed from 60 to 75.
- 20 Dec 2024 Status changed from not yet recruiting to recruiting.
- 17 Nov 2023 Interventional study model has been changed to Parallel from Single group assignment.